Logo.PNG
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
20 mars 2024 16h00 HE | HilleVax, Inc.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and...
Logo.PNG
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
05 févr. 2024 16h05 HE | HilleVax, Inc.
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Logo.PNG
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
18 janv. 2024 07h00 HE | HilleVax, Inc.
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
Logo.PNG
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
08 janv. 2024 07h00 HE | HilleVax, Inc.
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and...
Logo.PNG
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 18h28 HE | HilleVax, Inc.
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Logo.PNG
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
09 nov. 2023 16h05 HE | HilleVax, Inc.
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
Logo.PNG
HilleVax to Present at Upcoming Investor Conferences
01 nov. 2023 16h48 HE | HilleVax, Inc.
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Logo.PNG
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
26 sept. 2023 16h01 HE | HilleVax, Inc.
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Logo.PNG
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
25 sept. 2023 07h00 HE | HilleVax, Inc.
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Logo.PNG
HilleVax Announces Pricing of Public Offering of Common Stock
19 sept. 2023 20h05 HE | HilleVax, Inc.
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...